Contrasting predictors of severe primary graft dysfunction following transplant for chronic and acute respiratory failure.
Acute respiratory distress syndrome (ARDS)
lung transplant
primary graft dysfunction (PGD)
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
31 Aug 2024
31 Aug 2024
Historique:
received:
18
01
2024
accepted:
19
06
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
13
9
2024
Statut:
ppublish
Résumé
Lung transplantation represents a pivotal intervention for individuals grappling with end-stage lung diseases, and the role of lung transplantation in acute respiratory distress syndrome (ARDS) patients has garnered increased attention especially after the coronavirus disease 2019 (COVID-19) pandemic. Multiple studies have demonstrated a high incidence of primary graft dysfunction (PGD) in patients with ARDS compared to contemporaneous controls undergoing transplantation for chronic end-stage lung diseases although underlying mechanisms or risk factors remain unknown. This retrospective study investigates the contrasting risk factors for PGD grade 3 in patients with ARDS and chronic respiratory failure undergoing lung transplantation. The study included 293 patients who underwent lung transplantation from January 2018 through June 2023. We performed a multivariate logistic regression analysis using variables from the univariate logistic regression analyses to predict PGD grade 3. Our findings reveal distinct predictors for PGD grade 3 in the two cohorts. ARDS patients had higher incidence of PGD grade 3 than non-ARDS patients (30.2% This study highlights differing risk profiles for severe PGD in ARDS and non-ARDS lung transplant recipients, underscoring the need for tailored approaches in managing these patients. It paves the way for further research to refine strategies aimed at reducing PGD incidence and enhancing transplant outcomes in these distinct populations.
Sections du résumé
Background
UNASSIGNED
Lung transplantation represents a pivotal intervention for individuals grappling with end-stage lung diseases, and the role of lung transplantation in acute respiratory distress syndrome (ARDS) patients has garnered increased attention especially after the coronavirus disease 2019 (COVID-19) pandemic. Multiple studies have demonstrated a high incidence of primary graft dysfunction (PGD) in patients with ARDS compared to contemporaneous controls undergoing transplantation for chronic end-stage lung diseases although underlying mechanisms or risk factors remain unknown. This retrospective study investigates the contrasting risk factors for PGD grade 3 in patients with ARDS and chronic respiratory failure undergoing lung transplantation.
Methods
UNASSIGNED
The study included 293 patients who underwent lung transplantation from January 2018 through June 2023. We performed a multivariate logistic regression analysis using variables from the univariate logistic regression analyses to predict PGD grade 3.
Results
UNASSIGNED
Our findings reveal distinct predictors for PGD grade 3 in the two cohorts. ARDS patients had higher incidence of PGD grade 3 than non-ARDS patients (30.2%
Conclusions
UNASSIGNED
This study highlights differing risk profiles for severe PGD in ARDS and non-ARDS lung transplant recipients, underscoring the need for tailored approaches in managing these patients. It paves the way for further research to refine strategies aimed at reducing PGD incidence and enhancing transplant outcomes in these distinct populations.
Identifiants
pubmed: 39268121
doi: 10.21037/jtd-24-100
pii: jtd-16-08-5050
pmc: PMC11388248
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5050-5062Informations de copyright
2024 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-100/coif). The authors have no conflicts of interest to declare.
Références
J Thorac Dis. 2023 Jul 31;15(7):3751-3763
pubmed: 37559611
Lancet Respir Med. 2021 May;9(5):487-497
pubmed: 33811829
J Heart Lung Transplant. 2016 Jul;35(7):947-8
pubmed: 27235267
Lancet Respir Med. 2020 Oct;8(10):1057-1060
pubmed: 32857987
Artif Organs. 2022 Apr;46(4):688-696
pubmed: 34694655
J Clin Invest. 2022 Oct 17;132(20):
pubmed: 36250462
Sci Transl Med. 2020 Dec 16;12(574):
pubmed: 33257409
J Heart Lung Transplant. 2017 Oct;36(10):1097-1103
pubmed: 28942784
J Thorac Cardiovasc Surg. 2006 Jan;131(1):73-80
pubmed: 16399297
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24
pubmed: 7509706
JAMA. 2022 Feb 15;327(7):652-661
pubmed: 35085383
Crit Care Med. 2018 Nov;46(11):e1070-e1073
pubmed: 30095500
PLoS One. 2014 Mar 21;9(3):e92773
pubmed: 24658073
Am J Transplant. 2008 Nov;8(11):2454-62
pubmed: 18785961
Am J Respir Crit Care Med. 2007 Mar 1;175(5):507-13
pubmed: 17158279
Clin Transplant. 2021 Dec;35(12):e14480
pubmed: 34516007
Ann Thorac Surg. 2020 Oct;110(4):1209-1215
pubmed: 32173339
Curr Opin Organ Transplant. 2021 Jun 1;26(3):321-327
pubmed: 33938469
Am J Transplant. 2022 Jan;22(1):144-153
pubmed: 34254423
Am J Transplant. 2024 Mar;24(3):458-467
pubmed: 37468109
Am J Transplant. 2023 Feb;23(2 Suppl 1):S379-S442
pubmed: 37132345
ASAIO J. 2022 Jun 1;68(6):859-864
pubmed: 34593682
Am J Respir Crit Care Med. 2013 Mar 1;187(5):527-34
pubmed: 23306540
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Ann Thorac Surg. 2024 Jan;117(1):206-212
pubmed: 36521520
Am J Respir Crit Care Med. 2017 May 1;195(9):1253-1263
pubmed: 28459336
Chest. 2003 Oct;124(4):1232-41
pubmed: 14555551
Ann Am Thorac Soc. 2017 Oct;14(10):1514-1522
pubmed: 28719755
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
J Thorac Dis. 2023 Feb 28;15(2):399-409
pubmed: 36910052
Transplantation. 2019 Feb;103(2):336-343
pubmed: 29757910